PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      University of Wisconsin Carbone Cancer Center, Madison, WI, USA
      The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston, TX, USA
      The University of Texas MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Houston, TX, USA
      The University of Texas MD Anderson Cancer Center, Department of Diagnostic Radiology, Houston, TX, USA
      The University of Texas MD Anderson Cancer Center, Department of Biostatistics, Houston, TX, USA
      The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX, USA
      The University of Texas MD Anderson Cancer Center, Department of Pathology, Houston, TX, USA
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      Distinguishing well-differentiated liposarcoma (WDLPS) from dedifferentiated liposarcoma (DDLPS) is essential given distinct treatment paradigms and chemosensitivity. Percutaneous biopsy has a low sensitivity for detecting DDLPS. We sought to identify the diagnostic utility of positron emission tomography/computed tomography (PET/CT) in identifying WDLPS versus DDLPS. An independent radiologist reviewed PET/CT images to identify target lesions and determine the maximum standardized uptake value (SUVmax). An independent pathologist review confirmed WDLPS or DDLPS histology. A binary cutoff point of SUVmax was identified using a classification and regression trees (CART) algorithm. We identified 20 patients with WDLPS or DDLPS with 26 PET/CTs performed for separate recurrences that were followed by surgical sampling. Of the 26 records, 12 were DDLPS (46%) and 14 were WDLPS (54%). Patients with DDLPS had significantly higher SUVmax than those with WDLPS (p value = 0.0035). A SUVmax of 4 was identified as the cutoff point. Using this cutoff, the sensitivity of SUVmax identifying a case as DDLPS was 83.3% (95% CI: 51.6%, 97.9%) and the specificity was 85.7% (95% CI: 57.2%, 98.2%). PET/CT is a sensitive and specific diagnostic tool to identify the presence of dedifferentiation within the tumor.
    • Journal Subset:
      Biomedical; Europe; Peer Reviewed; UK & Ireland
    • ISSN:
      1357-714X
    • MEDLINE Info:
      NLM UID: 9709257
    • Publication Date:
      20200604
    • Publication Date:
      20200605
    • DOI:
      10.1155/2020/8363986
    • Accession Number:
      143523606
  • Citations
    • ABNT:
      PARKES, A. et al. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma, [s. l.], p. 1–6, 2020. DOI 10.1155/2020/8363986. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=143523606. Acesso em: 30 set. 2020.
    • AMA:
      Parkes A, Urquiola E, Bhosale P, et al. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. June 2020:1-6. doi:10.1155/2020/8363986
    • APA:
      Parkes, A., Urquiola, E., Bhosale, P., Lin, H., Watson, K., Wang, W.-L., Feig, B., Torres, K., Roland, C. L., Conley, A. P., Zarzour, M., Livingston, J. A., Ratan, R., Ludwig, J., Araujo, D. M., Ravi, V., Benjamin, R. S., Patel, S., & Somaiah, N. (2020). PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma, 1–6. https://doi.org/10.1155/2020/8363986
    • Chicago/Turabian: Author-Date:
      Parkes, Amanda, Elizabeth Urquiola, Priya Bhosale, Heather Lin, Kelsey Watson, Wei-Lien Wang, Barry Feig, et al. 2020. “PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma.” Sarcoma, June, 1–6. doi:10.1155/2020/8363986.
    • Harvard:
      Parkes, A. et al. (2020) ‘PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma’, Sarcoma, pp. 1–6. doi: 10.1155/2020/8363986.
    • Harvard: Australian:
      Parkes, A, Urquiola, E, Bhosale, P, Lin, H, Watson, K, Wang, W-L, Feig, B, Torres, K, Roland, CL, Conley, AP, Zarzour, M, Livingston, JA, Ratan, R, Ludwig, J, Araujo, DM, Ravi, V, Benjamin, RS, Patel, S & Somaiah, N 2020, ‘PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma’, Sarcoma, pp. 1–6, viewed 30 September 2020, .
    • MLA:
      Parkes, Amanda, et al. “PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma.” Sarcoma, June 2020, pp. 1–6. EBSCOhost, doi:10.1155/2020/8363986.
    • Chicago/Turabian: Humanities:
      Parkes, Amanda, Elizabeth Urquiola, Priya Bhosale, Heather Lin, Kelsey Watson, Wei-Lien Wang, Barry Feig, et al. “PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma.” Sarcoma, June 2020, 1–6. doi:10.1155/2020/8363986.
    • Vancouver/ICMJE:
      Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang W-L, et al. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma [Internet]. 2020 Jun [cited 2020 Sep 30];1–6. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=143523606